Peter Schultz recognized for his outstanding contributions to bioorganic and medicinal chemistry
Credit: Scripps Institue
Amsterdam, July 24, 2019 – Elsevier, a global information analytics business specializing in science and health, and the Board of Executive Editors of Elsevier’s Tetrahedron journal series, are pleased to announce that the 2019 Tetrahedron Prize for Creativity in Organic Chemistry has been awarded to Professor Peter Schultz, President and CEO of the Scripps Institute, La Jolla, CA, USA. Prof. Schultz receives this year’s award for his advances in fields of chemical biology and drug discovery.
Credited with the development and application of methods to expand the genetic code of living organisms, the discovery of catalytic antibodies, Prof. Schultz also expanded the application of molecular diversity technologies to address problems in chemistry, biology and medicine.
“I feel really quite honored to be a recipient of the Tetrahedron Prize,” said Professor Schultz said when receiving the news. “I’m enormously grateful to all of my ex-graduate students, postdocs and collaborators who are responsible for the science that this award recognizes.”
Awarded annually the Tetrahedron Prize for Creativity in Organic Chemistry was established in 1980 to honor the memory of the journal’s founding by the co-Chairmen of the Tetrahedron publications, Professor Sir Robert Robinson and Professor Robert Burns Woodward.
The award consists of a gold medal, a certificate and a monetary award of USD $15,000. The prize will be presented during the American Chemical Society’s 2020 Fall National Meeting in San Francisco, California, between August 16-20, 2020.
The Tetrahedron series consists of four premier journals publishing experimental and theoretical research results of outstanding significance and timeliness in the fields of organic, bioorganic and medicinal chemistry. Tetrahedron and Tetrahedron Letters deals with organic chemistry and related disciplines especially bio-organic chemistry. Bioorganic & Medicinal Chemistry and Bioorganic & Medicinal Chemistry Letters focus on medicinal chemistry, chemical biology and drug discovery and design, emphasizing new and emerging advances and concepts in these fields.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray’s Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. http://www.
+44 1865 584 3943